Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 272,255 shares of the company’s stock after buying an additional 8,533 shares during the quarter. JPMorgan Chase & Co.’s holdings in Prestige Consumer Healthcare were worth $19,630,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quest Partners LLC boosted its stake in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after purchasing an additional 433 shares during the period. nVerses Capital LLC boosted its position in Prestige Consumer Healthcare by 200.0% during the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank grew its holdings in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the period. Finally, International Assets Investment Management LLC increased its position in shares of Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $85.25.

Insider Activity

In related news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $74.45 on Friday. The firm has a 50-day simple moving average of $80.56 and a two-hundred day simple moving average of $74.17. The stock has a market cap of $3.68 billion, a PE ratio of 18.11, a P/E/G ratio of 2.32 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a 1-year low of $58.22 and a 1-year high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter last year, the firm earned $1.07 EPS. The firm’s revenue for the quarter was down .9% on a year-over-year basis. As a group, analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.